MAIA Biotechnology Files 8-K
Ticker: MAIA · Form: 8-K · Filed: Oct 24, 2025 · CIK: 1878313
Sentiment: neutral
Topics: corporate-filing, 8-K
TL;DR
MAIA Bio filed an 8-K on 10/24/25, standard corporate update.
AI Summary
MAIA Biotechnology, Inc. filed an 8-K on October 24, 2025, reporting other events and financial statements. The filing details the company's incorporation in Delaware and provides its principal executive office address in Chicago, IL.
Why It Matters
This 8-K filing serves as a public record of MAIA Biotechnology's corporate activities and financial reporting, providing transparency for investors and stakeholders.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks or material adverse information.
Key Players & Entities
- MAIA Biotechnology, Inc. (company) — Registrant
- October 24, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 444 West Lake Street, Suite 1700 Chicago, IL 60606 (address) — Principal executive offices
- 001-41455 (identifier) — Commission File Number
FAQ
What is the filing date of this 8-K report?
The filing date, and the date of the earliest event reported, is October 24, 2025.
What is the exact name of the registrant?
The exact name of the registrant is MAIA Biotechnology, Inc.
In which state was MAIA Biotechnology, Inc. incorporated?
MAIA Biotechnology, Inc. was incorporated in Delaware.
What is the company's principal executive office address?
The company's principal executive office is located at 444 West Lake Street, Suite 1700, Chicago, IL 60606.
What is the Commission File Number for MAIA Biotechnology, Inc.?
The Commission File Number for MAIA Biotechnology, Inc. is 001-41455.
Filing Stats: 478 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2025-10-24 16:30:43
Filing Documents
- form8-k.htm (8-K) — 37KB
- ex99-1.htm (EX-99.1) — 1KB
- ex99-1_001.jpg (GRAPHIC) — 1456KB
- 0001493152-25-019315.txt ( ) — 2206KB
- maia-20251024.xsd (EX-101.SCH) — 3KB
- maia-20251024_lab.xml (EX-101.LAB) — 33KB
- maia-20251024_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 24, 2025 MAIA BIOTECHNOLOGY, INC. By: /s/ Vlad Vitoc Name: Vlad Vitoc Title: Chief Executive Officer 3